Mitchell Mutz

EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023.

Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.

Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023.

EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023.